Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of darolutamide + ADT versus placebo + ADT in high-risk biochemical recurrence prostate cancer
CTR20233082Phase 3Active
- Sponsor
- Bayer
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide + ADT with Placebo + ADT (2 arms). Primary endpoint: Radiographic progression-free survival by PSMA PET/CT. Started Jun 2024; status: active.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20233082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233082.